Rapamycin is a powerful drug used to treat cancer, lung disease, organ transplant rejection and as a coating for coronary stents. It is also known as Sirolimus and Rapamune. When the drug was first discovered in 1972 it was used as an anti-fungal agent until researchers realized it had amazing healing properties.
Mikhail Blagosklonny has done extensive research on cancer and its treatments. He is a professor of Oncology at Rosewell Park Institute located in Buffalo, New York. He is also the editor in chief at Oncotarget where he has published a tremendous amount of research on aging. He is a believer in the powers of Rapamycin and advocates its use to increase human longevity. His contributions to science are unmatched.
Rapamycin is the preferred drug to treat organ transplant rejection because it is less toxic towards the kidneys. It also can be used to prevent new kidneys from contracting the disease Hemolytic-Uremic Syndrome after a transplant. Research is still ongoing to see if this drug may one day be used to cure Alzheimer’s disease. Research also has shown signs in mice that Rapamycin could be used to treat Muscular Dystrophy in humans. The drug also treats cancer by promoting tumor regression and boosting the immune system towards the disease.
Mikhail Blagosklonny is focused on getting people around the world the best medical treatment regardless of their economic situation. He specializes his research on cancer and aging. In specific, he wants to figure out the link between cancer and aging and why the disease is more prevalent in older people. Mikhail Blagosklonny is highly respected as a researcher and professor and continues to inspire his peers and students. His goal is to not only find cancer treatments, but to treat the disease effectively and affordably without debilitating side effects.
His desire is to eliminate cancer cells without destroying critical healthy cells that are needed to recover after treatment. He hopes that his hard work against this disease will inspire future researchers to continue on his legacy in hopes of eradicating the disease. He truly wants quality cancer treatment to be affordable for everybody, not just the privileged.
He truly believes that this drug has the potential to increase human longevity, but more research still needs to be done. His test concluded that Rapamycin helped fight tuberculosis in mice. Research also showed that the immune system in elderly patients was improved when given the drug prior to the flu vaccine.
Mikhail Blagosklonny is a renowned oncologist, professor, and a philanthropist. His passion for medical health has driven him into research specializing in cancer and aging process. He has devoted his time and resources to researching the correlation between old age and cancer. Mikhail contribution in this field is an inspiration to many including his student and colleagues. Mikhail Blagosklonny attended the First Pavlov State Medical University of St. Petersburg where studied M.D. in internal medicine. Later he earned his Ph.D. in cardiology and experimental medicine. He has worked as associate professor in medicine and then the senior scientist at Ordway Research Institute, Albany, New York. Currently, Mikhail Blagosklonny serves at Roswell Park Cancer Institute, New York, as a professor of oncology. Also, Mikhail is the Editor in Chief of the Oncotarget medical journal.
Rapamycin Healing Properties
Rapamycin or Sirolimus is a drug known in the market as Rapamune. Discovered in 1972 from bacterium samples, Sirolimus drug is known for preventing rejection in organ transplant. At first, Sirolimus was utilized as anti-fungal before the discovery of its high medicinal value. According to Mikhail Blagosklonny, Rapamycin has some of the following healing properties. Rapamycin contains immunosuppressant properties. Rapamune portrays a much less toxicity level towards kidney in the case of a transplant than any other drug. This low level is ideal for the patient diagnosed with the hemolytic-uremic syndrome. This rare condition is brought about the complexity of kidney failure, anemia, and low platelet count. Also, Rapamune is used to treat Lymphangioleiomyomatosis, a disease affecting women at the stage of bearing children.
Sirolimus is also used by doctors for coronary stents coating to hinder the re-stenosis occurring.The Sirolimus antiproliferative properties are perfect for the treatment of cancer. According to Blagosklonny, the drug can increase the body immune response towards tumors. Additionally, the research done patients with Tuberous Sclerosis Complex and Facial angiofibromas problem were cured after Rapamycin treatment. Mikhail Blagosklonny state that other investigations are in the prime stage concerning the treatment of Alzheimer diseases, Muscular Dystrophy, and Systemic Lupus Erythematosus by Rapamycin. Also, there is the steadfast belief from the successful research conducted on mice that Rapamycin can prolong the life of people.
Mikhail Plans for Oncology
Mikhail Blagosklonny dedication for the treatment of cancer has been enormous. His name is well known to scientific and research field of oncology. He has conducted numerous analyses, published many articles especially in Oncotarget journal and lectured as Professor of oncology for many years. His particular insight published in impactjournal.com elicited much interest in the world of medicine. Mikhail expectations of effectively and thoroughly treating cancer are an all-time high. He is committed to eliminating the cancerous cells from the body without affecting the crucial and healthy cells.His progress and interest within the field bring hopes as well as inspiration to many, more so to people living with cancer. Mikhail Blagosklonny expectations are thatt in future, cancer and deadly diseases treatment will be way easier as well as being affordable. His research on connections between aging and cancer is well progressing.
Oncotarget is a publishing company that publishes journals and distributes them on their online platform. Access to these publications is for free for all the websites clients. The releases are usually made on a weekly basis depending on the demand for the particular journals. Trending issues and topics at times determine the journal that will be published on Oncotargets website. The journals availed for its readers tend to cut across various disciplines hence the reason why the site is referred to as multidisciplinary. Over the years, Oncotarget has been striving to maximize the potential impact its published materials have on its audience while at the same time providing an insightful view to current issues within the scientific realm.
There has been an ongoing urgency by Oncotarget to abolish the boundaries within the biomedical specialties.With the leadership of the renowned scientists, Oncotarget has been providing researchers with journals that are aimed at contributing significantly to the development of sciences to one day achieve a life free from diseases.Oncotarget has been liaising closely with exemplary high-profile scientific indexes with the aim of providing all relevant scientific publications robustly to its clients. This has been well demonstrated by the collaboration between Oncotarget and IntegraGen.IntegraGen is a firm that has over the years specialized in the transformation of samples of biological data to genomic information and at times diagnostic equipment for Oncology.
Recently, news of the publishing of the analysis of tumor samples from patients who were undergoing the NEW EPOC clinical trial surfaced. Research carried out by IntegraGen show of a relationship between miR-31-3p expression and anti-EGFR treatment. There is the need to develop a tool that is capable of distinguishing patients who can benefit from this treatment option from those who can’t.As a business, Oncotarget doesn’t plan on being left behind with the 21st century’s technological wave. Currently, the firm is adopting new indexing algorithms aimed at the facilitation of dissemination of their scholarly Journals to relevant personnel within the sizeable medical research factions. Due to the increasing demand for Oncotargets journals, the company has shifted from publishing journals to their website one a week to the current rate of two Journals each week.
MIKHAIL BLAGOSKLONNY’S VIEW ON RAPAMYCIN
Scientists are always working towards inventing new things that make life better, longer and interesting. For the incurable diseases, they research relentlessly until they come up with a cure all in the effort of prolonging human life. The real struggle though has been inventing a solution for mortality and there seems to be some light at the end of the tunnel. Since researchers have come up with solutions of close to anything that causes death, now the target has been preventing aging. That means, however old one grows, age may never be a determining factor of one’s death. That way, immortality shall have been achieved for humans!Usually, age comes with certain diseases that in return lead to death. However, researchers have found out that rapamycin an anti aging drug can be used to prolong life and also improve a person’s immunity. In fact, the drug tested on animals proved to prolong the life of rodents.
Mikhail Blagosklonny on his Oncotarget publication, it was believed that aging was a functional decline resulting from molecular damage and could not be prevented. However, Mikhail differs with this theory. He supports the hyper function theory that describes aging as continued growth which can be prevented by use of rapamycin. Combined with other rapalogs in the correct dosage, rapamycin not only prevents disease but also promotes prolonged and healthy life in humans.Rapamycin’s journey began a couple of years ago and its future seems bright since researchers believe it is high time they start using the drug with a focus on aging. In 2006, the drug had been legalized for use in clinics for treatment of various diseases such as cancer and also the diseases that come hand in hand with aging. It was also recommended for use as an anti aging drug and also for transplant patients. A few years later, lots of tests had been done and just affirmed that indeed rapamycin held the future of anti aging therapy.
In his works, oncologist Mikhail argues that although rapamycin prolongs the lifespan of people, it doesn’t make much difference since finally, the person will die. According to him, the drug prolongs life, yes, but again prolonging life means delaying the diseases that come as a result of aging. Therefore, the cause of the death is all but the same. He adds that gerontologists should research on something else such as the potential causes of post aging given that rapamycin is already in clinics. Mikhail further argues that combining various anti aging drugs available in clinics and giving them in correct dosages and schedules is the best way to see maximum life span extension.Mikhail Blagosklonny is not only a researcher but also a professor and philanthropist who believes in fair treatment of all people regardless of their social status. His areas of interest in research are cancer and aging. His hope is to figure out a way of treating cancer patients effectively without destroying other crucial body cells at a cost friendly price.
Making contributions to propel never-before-seen research when it comes to the field of cutting-edge medicine at the Rutgers Cancer Institute which is located in New Jersey. Omar Boraie was recently awarded a newly-appointed chair that was named in his honor. Named the Omar Boraie Chair in Genomic Science, this endowed chair is considered the gold standard in higher education. It also expresses the commitment of a university to concentrate on an academic discipline at the highest levels to ensure its continued progression and support.
According to Yahoo.com, New Brunswick developer Omar Boraie was included in the 18 Chair Challenge, where an anonymous donor must match a $1.5 million support campaign at Rutgers University. The university formed 18 new chairs which included the New Jersey developer. The new Omar Boraie chair will help carve a new path for new discoveries in precision medicine and genomic science.
A Growing Field of Study
The field of genomic science and precision medicine has made profound changes on how professionals who work in the medical field approach how cancer is diagnosed and treated. This field is relatively new says the NY Times and involves tumor analysis and treatment using techniques that give doctors that opportunity to help patients at the genetic level. These analyses and treatments allow doctors to prescribe therapies that are individualized for each patient which result in better outcomes.
Rutgers at the Forefront
As one of the first medical treatment centers in the country as well as New Jersey to apply for genomic sequencing as a primary approach to patient care, Rutgers Cancer Institute remains a leader in performing advanced gene sequencing on tumors as a part of ongoing research at the university. For those who have rare cancer diseases or poor prognoses will highly benefit from this research. In addition, many people have treatment options which have been infected or limited, so genomic sequencing has been extremely helpful in finding unique therapies that were not available to patients with such circumstances in the past.
Recently Quoted on Newswise
In a recent article from Newswise (http://newswise.com/articles/omar-boraie-chair-in-genomic-science-established-at-rutgers-cancer-institute), Omar Boraie mentioned that physicians and scientists at Rutgers Cancer Institute are making huge advances precision medicine, especially for patients who are suffering from cancers that are no longer responsive. He also expressed that he is hopeful that the money he put forward will help others. In addition, he encouraged others to become an anonymous donor for the 18 Chair Challenge. He also hopes his family’s pledge to support the Rutgers Cancer Institute will inspire others to contribute as well. Boraie has been a long supporter of cancer research and this endowment furthers his vision to develop New Brunswick into a “Healthcare City”.